TOI RSI Chart
Last 7 days
-3.5%
Last 30 days
-31.0%
Last 90 days
-49.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 273.5M | 292.8M | 309.9M | 324.2M |
2022 | 209.6M | 220.7M | 233.4M | 252.5M |
2021 | 191.4M | 195.3M | 199.1M | 203.0M |
2020 | 0 | 0 | 0 | 187.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 29, 2024 | havencrest healthcare partners, l.p. | sold | -18,310 | 2.12 | -8,637 | - |
Jan 26, 2024 | havencrest healthcare partners, l.p. | sold | -14,935 | 2.14 | -6,979 | - |
Jan 25, 2024 | havencrest healthcare partners, l.p. | sold | -24,595 | 2.07 | -11,882 | - |
Jan 24, 2024 | havencrest healthcare partners, l.p. | sold | -57,304 | 2.3 | -24,915 | - |
Jan 23, 2024 | havencrest healthcare partners, l.p. | sold | -11,263 | 2.11 | -5,338 | - |
Jan 22, 2024 | havencrest healthcare partners, l.p. | sold | -21,757 | 2.12 | -10,263 | - |
Jan 19, 2024 | havencrest healthcare partners, l.p. | sold | -25,530 | 2.13 | -11,986 | - |
Dec 28, 2023 | havencrest healthcare partners, l.p. | sold | - | - | -8,561,050 | - |
Dec 26, 2023 | barasch richard a | acquired | - | - | 80,000 | - |
Dec 26, 2023 | o'meara maeve | acquired | - | - | 50,000 | - |
Which funds bought or sold TOI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -7.49 | -28,179 | 71,208 | -% |
Apr 25, 2024 | Fielder Capital Group LLC | unchanged | - | -32,289 | 110,903 | 0.05% |
Apr 24, 2024 | BROWN ADVISORY INC | unchanged | - | -8,590 | 29,505 | -% |
Apr 23, 2024 | KIRR MARBACH & CO LLC /IN/ | new | - | 330,652 | 330,652 | 0.08% |
Apr 18, 2024 | QUATTRO FINANCIAL ADVISORS LLC | new | - | 88,417 | 88,417 | 0.03% |
Mar 21, 2024 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | unchanged | - | 2,406 | 11,375 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.1 | 1,164,630 | 3,625,880 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -20,000 | - | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | new | - | 57,502 | 57,502 | -% |
Feb 14, 2024 | Davidson Kempner Capital Management LP | unchanged | - | 12,749 | 39,839 | -% |
Unveiling The Oncology Institute, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to The Oncology Institute, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 450.9B | 371.6B | 20.14 | 1.21 | ||||
CI | 104.2B | 195.3B | 19.4 | 0.53 | ||||
CVS | 84.9B | 357.8B | 10.16 | 0.24 | ||||
HCA | 82.4B | 65.0B | 15.71 | 1.27 | ||||
CNC | 39.5B | 155.5B | 14.44 | 0.25 | ||||
DVA | 12.1B | 12.1B | 17.52 | 1 | ||||
UHS | 11.7B | 14.3B | 16.33 | 0.82 | ||||
MID-CAP | ||||||||
CHE | 8.6B | 2.3B | 30.26 | 3.74 | ||||
ACHC | 6.9B | 2.9B | -317.8 | 2.35 | ||||
AMN | 2.3B | 3.8B | 10.69 | 0.59 | ||||
AMEH | 2.1B | 1.4B | 34.56 | 1.51 | ||||
SMALL-CAP | ||||||||
ADUS | 1.5B | 1.1B | 24.45 | 1.44 | ||||
BKD | 1.3B | 3.0B | -6.92 | 0.43 | ||||
BEAT | 54.0M | - | -3.69 | - | ||||
AMS | 20.6M | 21.3M | 38.6 | 0.96 |
The Oncology Institute, Inc. News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | 4.6% | 85,788,000 | 82,035,000 | 80,224,000 | 76,192,000 | 71,424,000 | 64,977,000 | 60,921,000 | 55,161,000 | 52,304,000 | 52,275,000 | 49,844,000 | 48,580,000 | - |
Operating Expenses | 5.3% | 101,076,000 | 95,960,000 | 95,162,000 | 109,059,000 | 96,503,000 | 85,074,000 | 79,225,000 | 73,632,000 | 93,136,000 | 54,432,000 | 50,960,000 | 50,333,000 | 53,948,560 |
S&GA Expenses | -0.4% | 28,090,000 | 28,205,000 | 28,726,000 | 28,830,000 | 29,572,000 | 31,963,000 | 28,348,000 | 29,806,000 | 48,245,000 | 12,730,000 | 11,212,000 | 11,178,000 | 41,680,688 |
EBITDA Margin | 0.1% | -0.26 | -0.26 | -0.22 | -0.19 | 0.00 | 0.00 | 0.01 | 0.06 | -0.04 | -0.02 | -0.02 | -0.06 | -0.06 |
Interest Expenses | 146.0% | 1,240,000 | -2,695,000 | -2,672,000 | -2,650,000 | -2,450,000 | -1,497,000 | -61,000 | -74,000 | -242,000 | -78,000 | 81,000 | 101,000 | 606,013 |
Income Taxes | -332.6% | -314,000 | 135,000 | 99,000 | 44,000 | -367,000 | -24,000 | -32,000 | 180,000 | -2,468,000 | 799,000 | 780,000 | 218,000 | -505,573 |
Earnings Before Taxes | -10.3% | -19,068,000 | -17,284,000 | -16,798,000 | -29,954,000 | -11,374,000 | -2,698,000 | -5,485,000 | 19,466,000 | -12,624,000 | -2,181,000 | 3,985,000 | -778,000 | -9,015,339 |
EBT Margin | -5.3% | -0.26 | -0.24 | -0.21 | -0.18 | 0.00 | -0.01 | 0.00 | 0.04 | -0.06 | -0.04 | -0.04 | -0.08 | -0.08 |
Net Income | -7.7% | -18,754,000 | -17,419,000 | -16,897,000 | -29,998,000 | -11,007,000 | -2,674,000 | -5,453,000 | 19,286,000 | -10,156,000 | -2,980,000 | 3,205,000 | -996,000 | -4.00 |
Net Income Margin | -5.4% | -0.26 | -0.24 | -0.21 | -0.18 | 0.00 | 0.00 | 0.00 | 0.04 | -0.05 | 0.00 | 0.00 | -0.03 | -0.03 |
Free Cashflow | 48.5% | -4,754,000 | -9,240,000 | -9,597,000 | -17,291,000 | -15,992,000 | -21,589,000 | -11,721,000 | -17,983,000 | -24,206,000 | -3,629,000 | -7,537,000 | -155,000 | 650,482 |
Balance Sheet | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2020Q1 | 2019Q4 |
Assets | -4.2% | 209 | 218 | 230 | 235 | 262 | 284 | 190 | 207 | 203 | 230 | 231 | 203 | 66.00 | 231 | 231 | 232 | 232 | - |
Current Assets | -6.0% | 143 | 153 | 104 | 119 | 130 | 144 | 112 | 140 | 154 | 0.00 | 1.00 | 1.00 | 30.00 | 1.00 | 1.00 | 2.00 | - | 0.00 |
Cash Equivalents | 21.6% | 33.00 | 28.00 | 29.00 | 15.00 | 14.00 | 61.00 | 64.00 | 96.00 | 115 | 12.00 | 15.00 | 27.00 | 6.00 | 1.00 | 1.00 | 2.00 | - | 2.00 |
Inventory | 12.4% | 14.00 | 12.00 | 12.00 | 10.00 | 9.00 | 10.00 | 9.00 | 8.00 | 6.00 | 6.00 | - | - | 4.00 | - | - | - | - | 4.00 |
Net PPE | 0.9% | 11.00 | 11.00 | 11.00 | 10.00 | 9.00 | 7.00 | 6.00 | 5.00 | 4.00 | 4.00 | - | - | 2.00 | - | - | - | - | 2.00 |
Goodwill | 0% | 7.00 | 7.00 | 7.00 | 5.00 | 21.00 | 0.00 | 34.00 | 27.00 | 27.00 | 16.00 | - | - | 14.00 | - | - | - | - | 14.00 |
Liabilities | 3.9% | 152 | 147 | 145 | 136 | 138 | 156 | 66.00 | 75.00 | 99.00 | 25.00 | 25.00 | 19.00 | 38.00 | 23.00 | 21.00 | 18.00 | 18.00 | - |
Current Liabilities | 7.4% | 35.00 | 32.00 | 34.00 | 30.00 | 30.00 | 33.00 | 36.00 | 32.00 | 30.00 | 4.00 | 3.00 | 0.00 | 29.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
Long Term Debt | 1.8% | 87.00 | 85.00 | 84.00 | 82.00 | 81.00 | 79.00 | - | - | - | - | - | - | 7.00 | - | - | - | - | - |
LT Debt, Current | - | - | - | - | - | - | - | - | - | 0.00 | 5.00 | - | - | 5.00 | - | - | - | - | - |
LT Debt, Non Current | 1.8% | 87.00 | 85.00 | 84.00 | 82.00 | 81.00 | 79.00 | - | - | - | - | - | - | 7.00 | - | - | - | - | - |
Shareholder's Equity | -20.6% | 57.00 | 72.00 | 85.00 | 98.00 | 123 | 128 | 124 | 132 | 104 | 48.00 | 50.00 | 47.00 | 28.00 | 5.00 | 5.00 | 5.00 | - | 42.00 |
Retained Earnings | -14.7% | -146 | -127 | -109 | -93.08 | -63.08 | -52.07 | -49.40 | -43.95 | -63.23 | -24.90 | -24.47 | -18.35 | -52.31 | -21.51 | -19.09 | -16.47 | -16.04 | 0.00 |
Additional Paid-In Capital | 2.0% | 204 | 200 | 196 | 191 | 186 | 180 | 173 | 176 | 167 | 0.00 | 14.00 | 8.00 | 80.00 | 11.00 | 8.00 | 6.00 | - | 0.00 |
Shares Outstanding | 0.6% | 74.00 | 74.00 | 73.00 | 74.00 | 73.00 | 73.00 | 73.00 | 73.00 | 73.00 | 66.00 | 64.00 | 63.00 | 59.00 | 6.00 | - | - | - | - |
Float | - | - | - | 42.00 | - | - | - | 126 | - | - | - | 179 | - | - | - | 173 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 | 2018Q3 |
Cashflow From Operations | 53.2% | -3,893 | -8,310 | -8,660 | -15,452 | -13,997 | -20,399 | -10,379 | -16,981 | -23,335 | -2,679 | -7,130 | 464 | 1,009 | -69.42 | -402 | -28.75 | - | -3,283 | - |
Share Based Compensation | -12.4% | 4,079 | 4,659 | 4,107 | 4,965 | 6,070 | 6,546 | 6,514 | 8,553 | 24,383 | 59.00 | 51.00 | 42.00 | - | - | - | - | - | - | - |
Cashflow From Investing | 50.8% | 11,627 | 7,709 | 24,903 | 18,401 | -32,571 | -87,779 | -10,262 | -1,002 | -9,151 | -950 | -607 | -1,446 | 221,156 | - | - | -230,000 | - | 2,815 | - |
Cashflow From Financing | -135.6% | -1,781 | -756 | -2,601 | -1,709 | -847 | 105,395 | -10,685 | -1,657 | 136,128 | -8.00 | -4,506 | 22,396 | -219,586 | -35.12 | -1.55 | 231,511 | 25.00 | - | - |
Buy Backs | -100.0% | - | 125 | 894 | - | - | - | 9,000 | - | - | - | - | - | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue | ||
Total operating revenue | $ 324,239 | $ 252,483 |
Operating expenses | ||
Goodwill impairment charges | 16,867 | 9,944 |
Selling, general and administrative expense | 113,851 | 119,689 |
Depreciation and amortization | 5,873 | 4,411 |
Total operating expenses | 401,257 | 334,434 |
Loss from operations | (77,018) | (81,951) |
Other non-operating expense (income) | ||
Interest expense, net | 6,777 | 4,082 |
Change in fair value of derivative warrant liabilities | 286 | (1,843) |
Change in fair value of earnout liabilities | (803) | (59,215) |
Change in fair value of conversion option derivative liabilities | (878) | (24,200) |
Gain on loan forgiveness | 0 | (183) |
Other, net | 704 | (501) |
Total other non-operating loss expense (income) | 6,086 | (81,860) |
Loss before provision for income taxes | (83,104) | (91) |
Income tax benefit (expense) | 36 | 243 |
Net income (loss) | (83,068) | 152 |
Net income (loss) per share attributable to common stockholders: | ||
Net income (loss) attributable to common stockholders, basic | $ (67,877) | $ 68 |
Weighted-average number of shares outstanding, basic (in shares) | 73,748,660 | 72,793,497 |
Net income (loss) per share attributable to common stockholders, basic (in usd per share) | $ (0.92) | $ 0 |
Net loss attributable to common stockholders, diluted | $ (67,877) | $ (16,980) |
Weighted-average number of shares outstanding, diluted (in shares) | 73,748,660 | 80,605,600 |
Net loss per share attributable to common stockholders, diluted (in usd per share) | $ (0.92) | $ (0.21) |
Patient services | ||
Revenue | ||
Total operating revenue | $ 213,504 | $ 166,785 |
Operating expenses | ||
Direct costs | 181,017 | 134,761 |
Dispensary | ||
Revenue | ||
Total operating revenue | 103,835 | 79,343 |
Operating expenses | ||
Direct costs | 83,071 | 65,111 |
Clinical trials & other | ||
Revenue | ||
Total operating revenue | 6,900 | 6,355 |
Operating expenses | ||
Direct costs | $ 578 | $ 518 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 33,488 | $ 14,010 |
Marketable securities | 49,367 | 59,796 |
Accounts receivable, net | 42,360 | 39,816 |
Other receivables | 551 | 617 |
Inventories | 13,678 | 9,261 |
Prepaid expenses and other current assets | 4,049 | 6,918 |
Total current assets | 143,493 | 130,418 |
Non-current investments | 0 | 58,354 |
Property and equipment, net | 10,883 | 8,547 |
Operating right of use assets | 29,169 | 24,494 |
Intangible assets, net | 17,904 | 17,957 |
Goodwill | 7,230 | 21,418 |
Other assets | 561 | 477 |
Total assets | 209,240 | 261,665 |
Current liabilities: | ||
Accounts payable | 14,429 | 9,372 |
Current portion of operating lease liabilities | 6,363 | 5,498 |
Income taxes payable | 0 | 255 |
Accrued expenses and other current liabilities | 13,996 | 14,595 |
Total current liabilities | 34,788 | 29,720 |
Operating lease liabilities | 26,486 | 22,060 |
Derivative warrant liabilities | 636 | 350 |
Derivative earnout liabilities | 0 | 803 |
Conversion option derivative liabilities | 3,082 | 3,960 |
Long-term debt, net of unamortized debt issuance costs | 86,826 | 80,621 |
Other non-current liabilities | 365 | 868 |
Deferred income taxes liability | 32 | 108 |
Total liabilities | 152,215 | 138,490 |
Commitments and contingencies (Note 15) | 0 | 0 |
Stockholders’ equity: | ||
Common Stock, $0.0001 par value, authorized 500,000,000 shares; 75,879,025 shares issued and 74,145,251 shares outstanding at December 31, 2023 and 73,265,621 shares issued and outstanding at December 31, 2022 | 8 | 7 |
Series A Convertible Preferred Stock, $0.0001 par value, authorized 10,000,000 shares; 165,045 shares issued and outstanding at December 31, 2023 and December 31, 2022 | 0 | 0 |
Additional paid-in capital | 204,186 | 186,250 |
Treasury Stock, Common, Value | (1,019) | 0 |
Accumulated deficit | (146,150) | (63,082) |
Total stockholders’ equity | 57,025 | 123,175 |
Total liabilities and stockholders’ equity | $ 209,240 | $ 261,665 |